Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orvepitant in Major Depressive Disorder
NCT00880048Phase 2Terminated
- Sponsor
- GSK
- Start
- Mar 2009
- Primary completion
- Jun 2010
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of orvepitant in major depressive disorder (MDD) (3 arms), sponsored by GSK. Primary endpoint: Change From Baseline in the 17-item Hamilton Depression Rating Scale Total Score at 6 weeks. Started Mar 2009; status: terminated.
02
Drugs
orvepitant
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00880048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00880048.